Navigation Links
New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
Date:1/21/2009

Nexomics Biosciences Inc., a recently-formed, New Jersey-based biotechnology company, applies cutting edge platform technologies based on large scale protein production, Nuclear Magnetic Resonance (NMR), and X-ray crystallography for use in drug discovery efforts. Nexomics Biosciences has signed a comprehensive license agreement with Rutgers, the State University of New Jersey, that provides Nexomics rights to a portfolio of intellectual property. An additional agreement has been announced with the Center for Advanced Biotechnology and Medicine that provides Nexomics access to laboratory space and equipment.

Highland Park, NJ (PRWEB) January 21, 2009 -- Nexomics Biosciences Inc., a recently-formed, New Jersey-based biotechnology company, applies cutting edge platform technologies based on large scale protein production, Nuclear Magnetic Resonance (NMR), and X-ray crystallography for use in drug discovery efforts. The company provides customers with services in bioinformatics, protein production and structural biology for lead discovery, optimization and development programs. In addition, Nexomics Biosciences will also pursue in-house drug discovery projects on proprietary targets to identify novel small molecule therapeutics.

Nexomics Biosciences has signed a comprehensive license agreement with Rutgers, the State University of New Jersey, that provides Nexomics rights to a portfolio of intellectual property, including a suite of bioinformatics software and an early stage antibiotic screening methodology. In addition, the agreement gives Nexomics rights to use and further develop a novel ribosomal RNA methyltransferase assay for identifying specific binding and inhibition of R1mA proteins from bacterial species. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.

An additional agreement has been announced with the Center for Advanced Biotechnology and Medicine (CABM), a research and teaching center that provides Nexomics access to laboratory space and equipment. Under the service agreement, Nexomics Biosciences will have access to a number of scientific facilities supporting molecular biology, fermentation, protein purification, and Nuclear Magnetic Resonance (NMR).

"Together with Prof. Gaetano Monteleone and co-founder Dr. Michael Baran, Rutgers is very excited to create Nexomics as a tool for commercializing promising technologies out of Prof. Monteleone's lab" said Dr. Michael Pazzani, Rutgers' V.P. of Research and Graduate and Professional Education. Dr. Pazzani further added "The unique and highly-regarded expertise of Nexomics' founders, as well as the company's strategy of providing drug discovery services to biotech and pharma companies while developing its own IP and drug candidates, bode well for a successful commercial effort."

About Nexomics Biosciences, Inc.
Nexomics Biosciences focuses on the discovery, development and commercialization of novel drugs for cancer, antiviral, and antibiotic treatments. Additionally, Nexomics also functions as a contract research organization (CRO), offering a broad array of gene-to-structure services to the biopharmaceutical community. By utilizing a fully integrated drug discovery pipeline, Nexomics offers a variety of services from bioinformatics, target profiling, gene cloning, recombinant protein expression, laboratory-scale fermentation, crystallization, NMR structural studies, X-ray crystallographic structural studies, and functional annotation. For more information about Nexomics Biosciences, visit www.nexomics.com

About Rutgers the State University of New Jersey's Office of Technology Commercialization
The mission of the Rutgers Office of Technology Commercialization is to work closely and supportively with Rutgers faculty and industry to secure corporate funding for Rutgers University faculty research for the public good as well as to identify, protect and license marketable Rutgers University inventions and intellectual property; and to make available additional discretionary income to Rutgers departments and centers, for furthering University research goals. For more information about the Rutgers Office of Technology Commercialization, visit www.otc.rutgers.edu

About The Center for Advanced Biotechnology & Medicine
Founded in 1985 and jointly administered by the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and by Rutgers, The State University of New Jersey, the mission of the Center for Advanced Biotechnology and Medicine (CABM) is to advance knowledge in the life sciences for the improvement of human health. CABM is also designated an advanced technology center by the NJ Commission on Science & Technology and is committed to economic development and public sevice through corporate alliances in research and education and by technology transfer and licensing. Completed in 1990, the 100,000 square foot CABM building is centrally located on the Busch/Piscataway campus. For more information about the CABM, visit www.cabm.rutgers.edu

###

Read the full story at http://www.prweb.com/releases/2009/01/prweb1887824.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. New Jersey-Based MedQuist Pays U.S. $6.6 Million to Resolve False Claims Act Allegations
2. Keane Wins $1 Million Electronic Medical Record (EMR) Implementation at New Jersey-Based Acute Care Facility
3. InNexus Biotechnology Completes Preclinical Study Confirming in Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting With FDA
4. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
5. Daniel J. Nevrivy, Ph.D., Biotech and Pharmaceutical Patent Attorney, Launches New Law Firm Aimed at Helping Clients Preserve Their Capital
6. Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results
7. Ezra Van Gelder Joins Microchip Biotechnologies as Executive Vice President R&D
8. Heska to Present at New York Society of Security Analysts 12th Annual Biotech and Specialty Pharma Conference
9. Investor Group Commends Clint Severson for Joining Trinity Biotechs Board of Directors
10. Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of Relapsed Ovarian Cancer
11. Accuray Incorporated Ranked Fifth in Deloittes Technology Fast 50 Program for Silicon Valley Scientific/Medical Equipment, and Biotechnology Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... 2017 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had won the ‘Clinical Supply Chain Excellence’ category ... International Exhibition & Convention Centre, Singapore. The award was presented at the conference ...
(Date:3/22/2017)... ... 2017 , ... Old School Labs™, makers of the best-selling Vintage line of ... Ambassador. Theophane, who trained with Floyd Mayweather, made his professional debut in London in ... an impressive number of wins in contests in Britain, Germany and the U.S. ...
(Date:3/22/2017)... ... March 22, 2017 , ... Wash Tower Ltd. has released a series of ... Tower, the world's first standalone constant pressure bidet. , The videos in the series ... https://www.washtower.com as well as on its social media pages. , Each video ...
(Date:3/22/2017)... SC (PRWEB) , ... March 22, 2017 , ... Drs. ... expanding their patient base to accept new patients in need of skilled pediatric ... experience, India Hook Dental Care offers pediatric patients routine treatments, including cavities, sealants and ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... core lab with extensive therapeutic experience and operational excellence in oncology clinical trials, ... clinical trial for the treatment of non-small cell lung cancer and small cell ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017 ... company specializing in the development of innovative peptide ... and metastatic disease, today announced that it will ... Dr. Glynn Wilson , Chairman ... of the company,s business, clinical pipeline and partnering ...
(Date:3/22/2017)... March 22, 2017 Hologic, Inc. (Nasdaq: ... the acquisition of Cynosure, Inc., a leader in medical ... cash. "We are pleased to complete our ... Michael Davin and the entire Cynosure team ... growing medical aesthetics market," said Steve MacMillan , ...
(Date:3/22/2017)... TFS is pleased to announce the appointment ... , two global executive positions in Medical Affairs and Clinical Development. ... Team and will report to Dr. Montse Barceló , Chief ... ... years of medical and scientific expertise gained across leading biopharmaceutical companies ...
Breaking Medicine Technology: